Showing 4521-4530 of 7117 results for "".
- Analysis Uncovers Health Economic Data for H.P. Acthar® Gel in Dermatomyositis and Polymyositishttps://practicaldermatology.com/news/analysis-uncover-health-economic-data-for-hp-acthar-gel-in-dermatomyositis-and-polymyositis/2458519/Results from two retrospective analyses sponsored by Mallinckrodt plc show that use of the company’s H.P. Acthar® Gel (repository corticotropin injection) offers a cost-effec
- Free Sunscreen Program Expands in Massachusetts Thanks to $25,000 Gifthttps://practicaldermatology.com/news/free-sunscreen-program-expands-in-mass-thanks-to-25000-gift/2458526/The Melanoma Foundation of New England (MFNE) received a $25,000 gift from the Arbella Insurance Foundation to allow its Practice Safe Skin program
- Galderma's Cetaphil® Launches Limited-edition Product Display Honoring Camp Wonderhttps://practicaldermatology.com/news/galdermas-cetaphil-launches-limited-edition-product-display-honoring-camp-wonder/2458529/Galderma Laboratories is unveiling a limited-edition product display in partnership with the Children's Skin Disease Foundation (CSDF) and Camp Wonder, an initiative of the CSDF. As part of a fi
- Solta Medical Launches Consumer Campaign to Empower LGBTQ Communityhttps://practicaldermatology.com/news/solta-medical-launches-consumer-campaign-to-empower-lgbtq-community/2458538/Solta Medical, a division of Valeant Pharmaceuticals North America LLC, is supporting the LGBTQ community through a focused consumer campaign that will help shed one more layer to reveal one’s true self. In addition, Solta Medical was the exclusive medical aesthetic category sponsor of the
- FDA Approves Juvéderm Volbella XC for Use in Lips and Perioral Rhytidshttps://practicaldermatology.com/news/fda-approves-juvderm-volbella-xc-for-use-in-lips-and-perioral-rhytids/2458546/Allergan plc, has received FDA approval to market Juvéderm Volbella XC for use in the lips for lip augmentation and for correction of perioral rhytids, commonly referred to as perioral lines, in adults over the age of 21. In clinical trials, Juvéderm Volbella XC was found to effecti
- FDA Accepts Allergan's NDA Filing for Oxymetazoline HCI Cream 1.0% for Facial Erythemahttps://practicaldermatology.com/news/fda-accepts-allergans-nda-filing-for-oxymetazoline-hci-cream-10/2458553/The FDA accepted Allergan plc's New Drug Application (NDA) filing for oxymetazoline HCl cream 1.0%, an investigational topical prescription product for the treatment of persistent facial erythema (redness) associated with rosacea in adults. Allergan expects the Prescription Drug User Fee
- Is Eli Lilly's Taltz the Next Blockbuster Drug for Psoriasis?https://practicaldermatology.com/news/is-eli-lillys-taltz-the-next-blockbuster-drug-for-psoriasis/2458569/Eli Lilly’s new psoriasis drug Taltz (ixekizumab) is set to generate sales in excess of $1 billion in the US and Europe by 2022 due to its efficacy and good safety profile, according to an analyst at GlobalData.
- Skin Cancer Expert Perry Robins, MD Joins Emerald's Advisory Boardhttps://practicaldermatology.com/news/skin-cancer-expert-perry-robins-md-joins-emeralds-advisory-board/2458574/New York City dermatologist Perry Robins, MD has joined Emerald Medical Applications Corp.’s advisory board. Emerald, an Israeli-based company, is developing DermaCompare™, a proprietary artificial intelligence free app 
- Use of Personal Care Products During Pregnancy Linked to Adverse Effects in Newbornshttps://practicaldermatology.com/news/use-of-personal-care-products-during-pregnancy-linked-to-adverse-effects-in-newborns/2458575/Personal care products used during pregnancy may be linked to adverse reproductive effects in newborns, report researchers from SUNY Downstate Medical Center’s School of Public Health. The long-term consequences of this are not clear and the findings must be reproduced in larg
- Joseph C. Papa Assumes Role Of Chairman And Chief Executive Officer Of Valeanthttps://practicaldermatology.com/news/joseph-c-papa-assumes-role-of-chairman-and-chief-executive-officer-of-valeant/2458580/Joseph C. Papa has assumed the role of Chairman and Chief Executive Officer at Valeant Pharmaceuticals International, Inc. As previously announced, Joseph C. Papa succeeds J. Michael Pearson. &quo